1.Clinical guidelines for the diagnosis and treatment of osteoporotic thoracolumbar vertebral fracture with kyphotic deformity in the elderly (version 2024)
Jian CHEN ; Qingqing LI ; Jun GU ; Zhiyi HU ; Shujie ZHAO ; Zhenfei HUANG ; Tao JIANG ; Wei ZHOU ; Xiaojian CAO ; Yongxin REN ; Weihua CAI ; Lipeng YU ; Tao SUI ; Qian WANG ; Pengyu TANG ; Mengyuan WU ; Weihu MA ; Xuhua LU ; Hongjian LIU ; Zhongmin ZHANG ; Xiaozhong ZHOU ; Baorong HE ; Kainan LI ; Tengbo YU ; Xiaodong GUO ; Yongxiang WANG ; Yong HAI ; Jiangang SHI ; Baoshan XU ; Weishi LI ; Jinglong YAN ; Guangzhi NING ; Yongfei GUO ; Zhijun QIAO ; Feng ZHANG ; Fubing WANG ; Fuyang CHEN ; Yan JIA ; Xiaohua ZHOU ; Yuhui PENG ; Jin FAN ; Guoyong YIN
Chinese Journal of Trauma 2024;40(11):961-973
The incidence of osteoporotic thoracolumbar vertebral fracture (OTLVF) in the elderly is gradually increasing. The kyphotic deformity caused by various factors has become an important characteristic of OTLVF and has received increasing attention. Its clinical manifestations include pain, delayed nerve damage, sagittal imbalance, etc. Currently, the definition and diagnosis of OTLVF with kyphotic deformity in the elderly are still unclear. Although there are many treatment options, they are controversial. Existing guidelines or consensuses pay little attention to this type of fracture with kyphotic deformity. To this end, the Lumbar Education Working Group of the Spine Branch of the Chinese Medicine Education Association and Editorial Committee of Chinese Journal of Trauma organized the experts in the relevant fields to jointly develop Clinical guidelines for the diagnosis and treatment of osteoporotic thoracolumbar vertebral fractures with kyphotic deformity in the elderly ( version 2024), based on evidence-based medical advancements and the principles of scientificity, practicality, and advanced nature, which provided 18 recommendations to standardize the clinical diagnosis and treatment.
2.A Study on the Influence of the Type of Finals on the Onset Time of the Stop Voice of Hearing Impaired Children
Yongxiang GAO ; Di WU ; Yan FENG ; Ye FENG ; Jiaru WANG ; Ying YU ; Chenghua TIAN
Journal of Audiology and Speech Pathology 2024;32(1):38-42
Objective To investigate the effect of final vowel types on the voice onset time(VOT)of differ-ent stops in children with hearing impairment,and to provide a basis for the acquisition and correction of stop sounds.Methods A total of 22 hearing-impaired children aged 3~6 and 22 children with normal hearing were ran-domly selected-18 consonant-vowel(CV)syllables composed of 6 stops and 3 single finals were recorded,using first tone.Using Praat 6.1.29 software to analyze and extract the stops VOT.Two-way ANOVA was used for each stop,the dependent variable was VOT,and the independent variables were hearing status and final type.Results Children in the hearing-impaired group had articulation errors in/t/,/g/,and/k/.Hearing status had significant effect on the main effect of plosives/g/,/p/,/t/,/k/(P<0.05),and the VOT of slurs/g/,/p/,/t/,/k/in the normal hearing group significantly greater than the hearing-impaired group(P<0.05).The main effect of finals on the VOT of the stops/b/,/p/and/t/was significant(P<0.05).Hearing status and final type had an interac-tive effect on the stop/t/,and the simple main effect showed that the difference in VOT of/ti/between the hear-ing-impaired group and the normal hearing group was greater than that of/ta/and/tu/.Conclusion The stops/g/,/p//t/,/k/VOT of hearing-impaired children are smaller than those of with normal hearing.The difference in VOT of/ti/sound between the hearing impaired group and the normal hearing group is greater than that of/ta/sound and/tu/sound.In the teaching of the initial/t/sound for hearing-impaired children,we can start with/ta/and/tu/with less difference,and the/ti/sound is consolidated later.Pay attention to breathing and oral exercise training,to lay a good foundation for clear pronunciation.
3.Progression in the treatment of female stress urinary incontinence with underactive bladder
Zilong LIANG ; Yifan SONG ; Haofeng PANG ; Jizong LYU ; Guanyu WU ; Yongxiang SHAO ; Lingchen KONG ; Baolin ZHUANG ; Weijun QIN ; Fei LIU
Journal of Modern Urology 2024;29(2):183-186
Stress urinary incontinence (SUI) and underactive bladder (UAB) are common types of lower urinary tract dysfunction in women.As the treatment mechanisms of the two conditions are contradictory, the treatment of SUI patients complicated with UAB remains a difficult clinical problem.In order to improve the treatment rate of such patients and promote research, this paper reviews the latest domestic and overseas diagnostic criteria of UAB, summarizes the treatment experience of conventional midurethral sling (tension-free vaginal tape or outside-in transobturator tape) and adjustable sling procedures (transobturator adjustable tape or Remeex system) combined with medication or intermittent catheterization, and the application prospects of cutting-edge technologies such as stem cell injection, cytokine therapy and gene therapy, so as to provide reference for clinicians and researchers.
4.Bladder hypersensitivity:the new mechanism of overactive bladder occurrence
Lingchen KONG ; Yongxiang SHAO ; Jizong LYU ; Guanyu WU ; Zilong LIANG ; Haofeng PANG ; Fei LIU
Journal of Modern Urology 2024;29(5):471-475
In recent years,with in-depth study of bladder sensation related mechanisms,numerous ion channels,neurotransmitters and nerve receptors have been found to participate in the regulation of bladder sensation,including TRPV,P2X and Piezo,as well as CBR and HCN.Thanks to the relevant research on the neural signal pathway from the cerebral cortex to the bladder wall and the maturity of clinical measurement methods for bladder sensation,we can further study the abnormal bladder sensation in patients with overactive bladder(OAB),so as to explore its mechanism.Bladder hypersensitivity,as one of the current research hotspots,is receiving increasing attention from researchers.This article reviews the mechanism of bladder hypersensitivity from the aspects of clinical measurement methods of bladder sensation,ion channel,neurotransmitters and nerve receptors related to bladder sensation,in order to explore its significance in the pathogenesis of OAB.
5.Research progress on neuroprotective effect and mechanism of spermidine
Chaoyong WANG ; Deyan CHEN ; Shuangshi WU ; Binjia RUAN ; Wanda ZHAN ; Fanhao WEI ; Yongxiang WANG
Journal of Clinical Medicine in Practice 2024;28(2):124-128
Spermidine, as a natural polyamine with high content in nerve cells, plays roles in regulating synaptic plasticity, promoting autophagy, and alleviating oxidative stress in the nervous system. Spermidine and polyamine metabolism may bring new therapeutic ideas for nervous system injury diseases. This paper reviewed the neuroprotective effects and mechanisms of spermidine in nervous system injury diseases.
6.Application of continuous quality improvement based on trauma team activation model in emergency triage
Yangchun ZHANG ; Xueli JI ; Li ZHANG ; Yongxiang WU ; Lili JIANG ; Kouying LIU
Chinese Journal of Modern Nursing 2023;29(12):1614-1619
Objective:To explore the application effect of continuous quality improvement based on trauma team activation model in emergency triage.Methods:This study is a historical controlled study. A total of 12 215 trauma patients receiving initial treatment in the Emergency Department of the First Affiliated Hospital with Nanjing Medical University from January 2020 to June 2021 were selected as the research objects by the convenience sampling method, and 3 896 trauma patients from January to June 2020 were enrolled as the baseline group, and 4 054 patients from July to December 2020 were enrolled as the phaseⅠ improvement group, and 4 265 patients from January to June 2021 were enrolled as the phaseⅡ improvement group. The baseline group adopted the one-tiered trauma team activation model, which was evaluated and decided by the first-visiting doctor. The phaseⅠ improvement group received the one-tiered trauma team activation model, which was evaluated and decided by pretest triage nurses. The stageⅡ improvement group conducted the two-tiered trauma team activation model, which was evaluated and decided by pretest triage nurses. The trauma team activation time, overtriage rate and undertriage rate were compared between the three groups.Results:The trauma team activation time of the phaseⅠ improvement group and phaseⅡ improvement group was shorter than that of the baseline group, and the difference was statistically significant ( P<0.05). The overtriage rate of the phaseⅡ improvement group was lower than that of the baseline group and the phaseⅠ improvement group, and the differences were statistically significant ( P<0.05). The underage rate of the three groups were <5%, and the differences were not statistically significant ( P>0.05) . Conclusions:The two-tiered activation of trauma team mode led by nurses can shorten the trauma team activation time, reduce the overtriage rate and undertriage rate, improve the quality of trauma team activation.
7.Data-driven engineering framework with AI algorithm of Ginkgo Folium tablets manufacturing.
Lijuan MA ; Jing ZHANG ; Ling LIN ; Tuanjie WANG ; Chaofu MA ; Xiaomeng WANG ; Mingshuang LI ; Yanjiang QIAO ; Yongxiang WANG ; Guimin ZHANG ; Zhisheng WU
Acta Pharmaceutica Sinica B 2023;13(5):2188-2201
Smart manufacturing still remains critical challenges for pharmaceutical manufacturing. Here, an original data-driven engineering framework was proposed to tackle the challenges. Firstly, from sporadic indicators to five kinds of systematic quality characteristics, nearly 2,000,000 real-world data points were successively characterized from Ginkgo Folium tablet manufacturing. Then, from simplex to the multivariate system, the digital process capability diagnosis strategy was proposed by multivariate Cpk integrated Bootstrap-t. The Cpk of Ginkgo Folium extracts, granules, and tablets were discovered, which was 0.59, 0.42, and 0.78, respectively, indicating a relatively weak process capability, especially in granulating. Furthermore, the quality traceability was discovered from unit to end-to-end analysis, which decreased from 2.17 to 1.73. This further proved that attention should be paid to granulating to improve the quality characteristic. In conclusion, this paper provided a data-driven engineering strategy empowering industrial innovation to face the challenge of smart pharmaceutical manufacturing.
8.Generation of αGal-enhanced bifunctional tumor vaccine.
Jian HE ; Yu HUO ; Zhikun ZHANG ; Yiqun LUO ; Xiuli LIU ; Qiaoying CHEN ; Pan WU ; Wei SHI ; Tao WU ; Chao TANG ; Huixue WANG ; Lan LI ; Xiyu LIU ; Yong HUANG ; Yongxiang ZHAO ; Lu GAN ; Bing WANG ; Liping ZHONG
Acta Pharmaceutica Sinica B 2022;12(7):3177-3186
Hepatocellular carcinoma (HCC) is a common malignant tumor with poor prognosis and high mortality. In this study, we demonstrated a novel vaccine targeting HCC and tumor neovascular endothelial cells by fusing recombinant MHCC97H cells expressing porcine α-1,3-galactose epitopes (αGal) and endorphin extracellular domains (END) with dendritic cells (DCs) from healthy volunteers. END+/Gal+-MHCC97H/DC fusion cells induced cytotoxic T lymphocytes (CTLs) and secretion of interferon-gamma (IFN-γ). CTLs targeted cells expressing αGal and END and tumor angiogenesis. The fused cell vaccine can effectively inhibit tumor growth and prolong the survival time of human hepatoma mice, indicating the high clinical potential of this new cell based vaccine.
9.Efficacy and safety of neoadjuvant immunotherapy for hepatocellular carcinoma
Yongxiang XIA ; Hui ZHANG ; Feng ZHANG ; Xiangcheng LI ; Dawei RONG ; Weiwei TANG ; Hengsong CAO ; Jie ZHAO ; Ping WANG ; Liyong PU ; Xiaofeng QIAN ; Feng CHENG ; Ke WANG ; Lianbao KONG ; Chuanyong ZHANG ; Donghua LI ; Jinhua SONG ; Aihua YAO ; Xiaofeng WU ; Chen WU ; Xuehao WANG
Chinese Journal of Surgery 2022;60(7):688-694
Objective:To study the surgical safety and efficacy of preoperative neoadjuvant therapy with immune checkpoint inhibitors combined with anti-angiogenic drugs in patients with China liver cancer staging(CNLC)-Ⅱb and Ⅲa resectable hepatocellular carcinoma.Methods:The data of 129 patients with Ⅱb and Ⅲa hepatocellular carcinoma who underwent surgery at the First Affiliated Hospital of Nanjing Medical University from January 2018 to December 2020 were analyzed. All patients were divided into two groups: the neoadjuvant therapy group( n=14,13 males and 1 female,aged (55.4±12.6)years(range:34 to 75 years)) received immune combined targeted therapy before surgery,immune checkpoint inhibitor camrelizumab was administered intravenously at a dose of 200 mg each time,every 2 weeks for 3 cycles,anti-angiogenesis drug apatinib was taken orally and continuously with a dose of 250 mg for 3 weeks and the conventional surgery group( n=115,103 males and 12 females,aged (55.8±12.0)years(range:21 to 83 years)) did not receive antitumor systemic therapy before surgery. There were 3 patients with CNLC-Ⅱb,11 with CNLC-Ⅲa in the neoadjuvant group;28 patients with CNLC-Ⅱb,87 with CNLC-Ⅲa in the conventional group. Student′s t test or rank-sum test was used to compare the differences between two groups for quantitative data, Fisher′s exact probability method was used to compare the differences of proportions between two groups, and Log-rank test was used to compare survival differences between two groups. Results:The 1-year recurrence rate in the neoadjuvant group was 42.9%,and the 1-year recurrence rate in the conventional group was 64.0%,with a statistically significant difference between the two groups(χ2=3.850, P=0.050);The 1-year survival rate in the neoadjuvant group was 100% and that in the conventional group was 74.2%,with a statistically significant difference between the two groups(χ2=5.170, P=0.023). According to the stratified analysis of the number of tumors,for single tumor,the 1-year recurrence rate in the neoadjuvant group was 25.0%,and that in the conventional surgery group was 71.0%,and the difference between the two groups was statistically significant(χ2=5.280, P=0.022). For multiple tumors, the 1-year recurrence rate in the neoadjuvant group was 66.7%,and the 1-year recurrence rate in the conventional surgery group was 58.9%,with no significant difference between the two groups(χ2=0.110, P=0.736). The operative time,intraoperative blood loss,and postoperative hospital stay in the neoadjuvant group were similar to those in the conventional group,and their differences were not statistically significant. Conclusions:Immune checkpoint inhibitors combined with anti-angiogenic targeted drugs as a neoadjuvant therapy for resectable hepatocellular carcinoma can reduce the 1-year recurrence rate and improve the 1-year survival rate,especially for those with solitary tumor. Limited by the sample size of the neoadjuvant group,the safety of immune combined targeted therapy before surgery cannot be observed more comprehensively,and further studies will be explored.
10.Efficacy and safety of neoadjuvant immunotherapy for hepatocellular carcinoma
Yongxiang XIA ; Hui ZHANG ; Feng ZHANG ; Xiangcheng LI ; Dawei RONG ; Weiwei TANG ; Hengsong CAO ; Jie ZHAO ; Ping WANG ; Liyong PU ; Xiaofeng QIAN ; Feng CHENG ; Ke WANG ; Lianbao KONG ; Chuanyong ZHANG ; Donghua LI ; Jinhua SONG ; Aihua YAO ; Xiaofeng WU ; Chen WU ; Xuehao WANG
Chinese Journal of Surgery 2022;60(7):688-694
Objective:To study the surgical safety and efficacy of preoperative neoadjuvant therapy with immune checkpoint inhibitors combined with anti-angiogenic drugs in patients with China liver cancer staging(CNLC)-Ⅱb and Ⅲa resectable hepatocellular carcinoma.Methods:The data of 129 patients with Ⅱb and Ⅲa hepatocellular carcinoma who underwent surgery at the First Affiliated Hospital of Nanjing Medical University from January 2018 to December 2020 were analyzed. All patients were divided into two groups: the neoadjuvant therapy group( n=14,13 males and 1 female,aged (55.4±12.6)years(range:34 to 75 years)) received immune combined targeted therapy before surgery,immune checkpoint inhibitor camrelizumab was administered intravenously at a dose of 200 mg each time,every 2 weeks for 3 cycles,anti-angiogenesis drug apatinib was taken orally and continuously with a dose of 250 mg for 3 weeks and the conventional surgery group( n=115,103 males and 12 females,aged (55.8±12.0)years(range:21 to 83 years)) did not receive antitumor systemic therapy before surgery. There were 3 patients with CNLC-Ⅱb,11 with CNLC-Ⅲa in the neoadjuvant group;28 patients with CNLC-Ⅱb,87 with CNLC-Ⅲa in the conventional group. Student′s t test or rank-sum test was used to compare the differences between two groups for quantitative data, Fisher′s exact probability method was used to compare the differences of proportions between two groups, and Log-rank test was used to compare survival differences between two groups. Results:The 1-year recurrence rate in the neoadjuvant group was 42.9%,and the 1-year recurrence rate in the conventional group was 64.0%,with a statistically significant difference between the two groups(χ2=3.850, P=0.050);The 1-year survival rate in the neoadjuvant group was 100% and that in the conventional group was 74.2%,with a statistically significant difference between the two groups(χ2=5.170, P=0.023). According to the stratified analysis of the number of tumors,for single tumor,the 1-year recurrence rate in the neoadjuvant group was 25.0%,and that in the conventional surgery group was 71.0%,and the difference between the two groups was statistically significant(χ2=5.280, P=0.022). For multiple tumors, the 1-year recurrence rate in the neoadjuvant group was 66.7%,and the 1-year recurrence rate in the conventional surgery group was 58.9%,with no significant difference between the two groups(χ2=0.110, P=0.736). The operative time,intraoperative blood loss,and postoperative hospital stay in the neoadjuvant group were similar to those in the conventional group,and their differences were not statistically significant. Conclusions:Immune checkpoint inhibitors combined with anti-angiogenic targeted drugs as a neoadjuvant therapy for resectable hepatocellular carcinoma can reduce the 1-year recurrence rate and improve the 1-year survival rate,especially for those with solitary tumor. Limited by the sample size of the neoadjuvant group,the safety of immune combined targeted therapy before surgery cannot be observed more comprehensively,and further studies will be explored.


Result Analysis
Print
Save
E-mail